Why President Trump Is Targeting India: Trade Deficits, Russian Oil and the Push to Reshore Pharma
President Donald Trump’s second-term trade policy has repeatedly placed India under intense pressure. Through a series of escalating and then partially rolled-back tariffs, public statements, and sector-specific threats, Washington has singled out New Delhi on issues ranging from the bilateral goods trade imbalance to purchases of Russian crude oil and, most recently, the supply of generic medicines. The pattern is not random. It reflects three overlapping priorities of the Trump administration: reducing large U.S. trade deficits, using economic leverage against Russia, and forcing the onshoring of critical manufacturing. Understanding these drivers explains both the severity of the measures and the fluctuations in U.S.-India economic relations since early 2025.
The first and most consistent complaint from the White House has been the size of the U.S. goods trade deficit with India. In recent years that deficit has hovered between $45 billion and $58 billion, making India one of the more significant sources of imbalance among major trading partners. Trump has long argued that persistent deficits signal unfair treatment of American exporters. In India’s case the administration points to high average tariffs, especially on agricultural products, dairy, automobiles and certain industrial goods, as well as a range of non-tariff barriers that limit market access for U.S. companies.
When Trump returned to office he declared a national emergency over “large and persistent” goods trade deficits caused by a lack of reciprocity. Reciprocal tariffs became the central instrument. India was assigned rates that at times reached 25 percent and, with additional penalties, climbed toward 50 percent on a broad range of exports. These duties hit labour-intensive sectors such as textiles, apparel, leather, footwear, jewellery and certain chemicals that form the backbone of India’s export basket to the United States. Indian officials countered that their tariffs protect farmers and nascent industries in a developing economy, and that the overall bilateral relationship encompasses far more than merchandise trade, including services, defence cooperation and technology. Washington remained unconvinced that the existing arrangement was reciprocal.
The second major source of friction has been India’s purchases of Russian oil. After the 2022 invasion of Ukraine, India emerged as one of the largest buyers of discounted Russian crude. Those imports helped New Delhi manage domestic energy costs and keep inflation in check, but they also provided Moscow with significant hard-currency revenue. Trump framed the trade as effectively subsidising Russia’s war effort. In mid-2025 the administration layered an extra 25 percent tariff on Indian goods specifically as a penalty for continued Russian oil purchases, pushing the combined rate to among the highest imposed on any major partner.
The pressure produced results, at least on paper. In early 2026, after high-level conversations between Trump and Prime Minister Narendra Modi, the White House announced that India had committed to stop or sharply reduce imports of Russian oil and to expand purchases of U.S. energy products. In return, Trump signed an executive order removing the additional 25 percent penalty and lowering the reciprocal tariff rate to 18 percent. A framework for an interim trade agreement was unveiled, under which India agreed to reduce or eliminate tariffs on a range of American industrial and agricultural goods. The episode illustrated the transactional nature of the relationship: tariff relief was explicitly conditioned on geopolitical alignment regarding Russia.
Even after that partial de-escalation, trade tensions did not disappear. Negotiations toward a fuller bilateral trade agreement have proceeded slowly. U.S. negotiators continue to press for deeper agricultural market access, greater openness for American dairy and wine, and reductions in non-tariff barriers. Indian officials have sought greater certainty on tariffs, relief for labour-intensive exports, and recognition of India’s development needs. The process has been complicated by domestic political sensitivities on both sides and by the administration’s broader America First industrial policy.
The third and most recent front is pharmaceuticals. In July 2026 Trump announced a phased tariff roadmap for imported generic medicines. Under the plan, generics would remain tariff-free for two years beginning in August 2026, after which duties would rise to 100 percent for one year and then to 200 percent. Companies that fail to establish manufacturing capacity inside the United States within the timeline face penalties. The explicit goal is to reshore production of generic drugs, strengthen domestic supply chains, and reduce dependence on foreign sources.
India is the world’s largest supplier of generic medicines and accounts for roughly 40 percent of the volume of generics consumed in the United States. Indian companies export several billion dollars’ worth of these medicines annually to the American market, often at prices far below those of branded alternatives. The proposed tariffs therefore strike at a sector in which India holds a clear comparative advantage built over decades of investment in manufacturing scale, regulatory compliance with the U.S. Food and Drug Administration, and low production costs. Industry analysts in India have noted that building equivalent capacity in the United States would take years and raise costs substantially, potentially leading to higher medicine prices for American patients or temporary shortages if the transition is poorly managed. Nevertheless, the administration has presented the policy as a matter of national security and economic resilience.
Taken together, these three strands reveal a coherent if abrasive strategy. Trump’s approach treats trade policy as a tool of both economic rebalancing and geopolitical leverage. India is large enough, and its market sufficiently protected in sensitive sectors, to attract sustained attention. At the same time, the strategic partnership between the two countries—especially the shared interest in countering Chinese influence in the Indo-Pacific—has prevented a complete rupture. High-level diplomacy continues, defence cooperation has expanded, and both sides still speak of a long-term goal of substantially increasing bilateral trade.
For India the costs have been real. Exporters in textiles, gems and jewellery, and other tariff-exposed sectors have faced compressed margins and uncertainty. The pharmaceutical industry now confronts a multi-year timeline that could force difficult investment decisions about locating production in the United States. New Delhi has responded by accelerating free-trade negotiations with other partners, seeking to diversify export destinations, and emphasising domestic manufacturing under the Atmanirbhar Bharat umbrella. It has also sought to demonstrate flexibility on energy purchases and selective tariff reductions in order to keep the relationship with Washington functional.
From the American perspective the pressure is framed as correcting decades of what the administration calls unfair trade practices and reducing strategic vulnerabilities. Whether the tariffs ultimately succeed in shrinking the goods deficit, ending Russian oil purchases permanently, or relocating significant generic drug production remains an open question. Building pharmaceutical manufacturing capacity is capital-intensive and subject to complex regulatory timelines. Trade diversion and higher costs for U.S. consumers are possible side-effects. Still, the direction of policy is clear: the United States under Trump is willing to use tariff power aggressively against partners that do not align sufficiently on its economic and geopolitical priorities.
The U.S.-India relationship has therefore entered a more transactional and contested phase. Friendship between leaders and overlapping strategic interests continue to provide a floor under the partnership. Yet the ceiling is now defined by hard bargaining over market access, energy choices and industrial location. For the foreseeable future, India’s exporters and policymakers will have to navigate a landscape in which tariff threats, conditional relief and sector-specific industrial policies remain central features of engagement with Washington. The pattern of pressure is unlikely to disappear as long as the underlying imbalances and strategic differences persist.
About The Author
